G

GSK

Develops medicines, vaccines, and consumer health

Principal IAM Lifecycle Management

Full-TimeUpdated Deadline 11/10/26
No salary listed
Expert
Bachelor's
Bengaluru, Karnataka, India
Hybrid
CybersecuritySecurity Engineering & Architecture

About the job

Requirements
  • A bachelor's degree in Computer Science, Information Technology, or a related discipline, or equivalent practical experience.
  • Ten or more years of relevant IAM experience, including significant hands-on engineering and technical ownership of complex identity and account lifecycle implementations.
  • Strong implementation experience with an enterprise Identity Governance and Administration platform such as SailPoint, Saviynt, LINX, or an equivalent product.
  • Proven experience designing and delivering lifecycle solutions for joiner, mover, leaver, rehire, employee, contractor, partner, and non-human identity scenarios.
  • Deep understanding of provisioning and deprovisioning workflows, approval orchestration, birthright and role-based access, account-state transitions, exception handling, and policy enforcement.
  • Strong knowledge of identity data models, account correlation, reconciliation, access reviews, certification, segregation of duties, orphan-account prevention, and audit evidence.
  • Experience integrating IAM platforms with HR systems, Active Directory, Microsoft Entra ID, LDAP, databases, SaaS platforms, and custom applications.
  • Strong engineering capability with REST APIs, JSON, SQL, scripting, and secure event-driven integration patterns, with the ability to troubleshoot transactions across connected systems.
  • Experience owning application onboarding and complex cross-functional technical delivery from design through testing, deployment, and operational handover.
  • Experience delivering secure, observable, and resilient IAM services using automated testing, Git-based version control, and CI/CD pipelines such as GitHub or Azure DevOps.
  • Strong troubleshooting and root-cause analysis skills across distributed IAM services, integrations, workflows, and data flows.
  • Ability to mentor engineers and communicate complex technical concepts clearly to engineering, product, business, risk, and audit stakeholders.
Responsibilities
  • Own complex IAM lifecycle workstreams from discovery and requirements analysis through solution design, configuration, testing, deployment, and operational transition.
  • Act as the senior technical subject matter expert for IAM Lifecycle Management, advising product, architecture, engineering, security, risk, audit, and business stakeholders.
  • Mentor engineers, review solution designs and code, and establish reusable patterns, standards, documentation, and engineering practices.
  • Design and deliver end-to-end identity and account lifecycle capabilities, including creation, provisioning, modification, suspension, recertification, and deprovisioning across on-premises, cloud, and SaaS systems.
  • Drive joiner, mover, leaver, rehire, contractor, partner, and non-human identity lifecycle scenarios, including trigger events, approval orchestration, account states, exception handling, and recovery controls.
  • Drive complex application onboarding initiatives and integrations between authoritative HR and identity sources, directories, IGA platforms, and target applications using connectors, APIs, and event-driven services.
  • Implement and improve governance controls for least privilege, segregation of duties, birthright and role-based access, account ownership, orphan-account prevention, access reviews, and policy compliance.
  • Drive improvements in identity correlation, reconciliation, source-data quality, reporting, monitoring, observability, and engineering telemetry to improve lifecycle accuracy and service reliability.
  • Own root-cause analysis and resolution of complex lifecycle defects, control failures, production incidents, and cross-platform integration issues.
  • Contribute technical insight to product roadmaps, technology assessments, and delivery planning, identifying dependencies, risks, and opportunities for automation, resilience, and user-experience improvement.
  • Promote secure engineering, automated testing, CI/CD, API governance, accessibility, performance optimisation, observability, and controlled deployment practices.
  • Ensure IAM processes, implementation evidence, and control operation meet regulatory, audit, and risk-management requirements, including those of highly regulated environments.
Desired Qualifications
  • Advanced implementation experience with a SaaS-based identity security or leading IGA platform, including workflow, connector, and policy configuration.
  • Experience modernising or migrating legacy or bespoke lifecycle solutions to a SaaS IGA platform.
  • Experience designing serverless, containerised, or event-driven integration services in Microsoft Azure.
  • Hands-on experience with GraphQL, TypeScript, Node.js, Next.js, NestJS, Apollo, .NET, or API federation where these support IAM integration, administration, and self-service experiences.
  • Experience applying API-first, microfrontend, reusable component, secure coding, and automated testing practices in enterprise applications.
  • Experience with policy-as-code, identity analytics, automated testing, and engineering telemetry for IAM capabilities.
  • Experience applying AI or analytics to identity-data quality, access recommendations, anomaly detection, or governance improvement, and knowledge of identity controls for AI agents and other non-human identities.
  • Experience with control frameworks such as SOX and GxP and producing evidence suitable for regulated environments.
  • Relevant IAM, cloud, or security certification, such as CISSP, SailPoint, Saviynt, CIMP, or Microsoft Azure.
  • Experience working in a central IT or cyber security team within pharmaceuticals, healthcare, financial services, or another highly regulated industry.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
  • GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
  • Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

  • Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
  • Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
  • Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

  • GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
  • Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
  • GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Wellness Program
  • Mental Health Support
  • Phone/Internet Stipend

Company News

Yahoo Finance
Oct 28th, 2026
GSK Q3 sales rise 5% to $11.3B as specialty medicines drive growth, 2026 guidance reaffirmed

GSK reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, driven by specialty medicines. Core operating profit rose 5%, while core earnings per share rose 1%. The company reaffirmed its 2026 guidance, expecting sales and core operating profit in the upper half of their ranges. Higher interest costs after the $10.6 billion Nuvalent acquisition will hold core earnings per share growth in the lower half of its range. Specialty medicines grew 15%, led by Cabenuva, up 35%. Vaccines sales fell 2% on Shingrix destocking in China. Research and development spending rose 22%. GSK has started 18 phase III studies this year and expects four more. It declared a third-quarter dividend of 17 pence per share.

Yahoo Finance
Oct 28th, 2026
GSK shares slide as pipeline doubts and weak vaccine sales offset $11.3B sales beat

GSK shares fell about 4% on October 28 despite a third-quarter sales and profit beat, as investors focused on pipeline doubts and weak vaccine sales, including shingles shot Shingrix. The stock fell as much as 7.3% earlier in the day. Core profit was 54.6 pence per share on turnover of £8.89 billion, against expectations of 50.4 pence and £8.84 billion. Specialty medicines for HIV, respiratory conditions and cancer rose 15%, but sales of new asthma drug Exdensur and vaccines missed forecasts. Chief executive officer Luke Miels is running a £1.9 billion ($2.5 billion) cost-savings plan to fund drug development ahead of patent losses. Market forecasts for 2031 sales of £36.64 billion trail GSK's target of more than £40 billion. GSK kept its annual outlook and took a £328 million restructuring charge in the quarter.

Yahoo Finance
Oct 28th, 2026
FTSE 100 slips 0.3% ahead of budget as GSK falls 4.3% and Unilever drops 3.4% despite earnings beats

British stocks fell on Wednesday as investors awaited the budget and weighed results from GSK and Unilever. The FTSE 100 was down 0.30% at 08:18 GMT, extending Tuesday's fall. GSK was the top loser, down 4.3%, despite beating third-quarter expectations. Core earnings per share were 54.6 pence against a consensus of 50.4 pence, and revenue was £8.89 billion. Unilever fell 3.38% even after it raised its volume growth forecast to at least 3%. Finance Minister John Healey said he would scrap gas standing charges, which cost the typical household £108 a year. Standard Chartered raised its full-year targets after third-quarter pretax profit jumped 27% to $2.25 billion. Brent futures rose 1.4% to $110.91 a barrel.

Yahoo Finance
Oct 28th, 2026
GSK holds guidance as specialty drugs lift sales 5% to $11.3B, but $417M charge cuts profit 16%

GSK kept its 2026 guidance after specialty medicines drove another quarter of growth, though a £328 million restructuring charge cut its profit. Sales rose 5% at constant exchange rates to £8.9 billion. Core operating profit rose 5% to £3.1 billion, while total operating profit fell 16% to £2.1 billion. The charge relates to Accelerate Growth, a cost-cutting programme that targets £1.9 billion of annual savings by 2029 at a total cost of £2.4 billion. GSK plans to put the savings mainly into research and development. Specialty medicines grew 15% to £3.9 billion, while vaccines fell 2% to £2.6 billion. Net debt rose to £20.7 billion from £14.5 billion at the end of 2025, after the $10.8 billion Nuvalent takeover. Chief executive Luke Miels said GSK had "delivered another strong quarter.

Yahoo Finance
Oct 27th, 2026
GSK's oncology push: Jemperli FDA approval and strong ADC data at ESMO for $97.4B group

GSK presented late-stage oncology data at the ESMO Congress in October 2026 on three drugs: Jemperli, Mo-Rez and Ris-Rez. The £76.7 billion pharmaceuticals group is leaning on oncology as a key part of its mix. The US Food and Drug Administration (FDA) granted Jemperli accelerated approval for MSI-H/dMMR locally advanced rectal cancer. In the AZUR-1 trial, 71% of patients received dostarlimab alone, without additional treatment or progression in the assessment window. Mo-Rez showed a 62% confirmed response rate in platinum-resistant ovarian and endometrial cancers, with a median duration of 12.2 months. Ris-Rez delivered a 61% objective response rate in extensive stage small cell lung cancer. Investors should watch the phase III trials and AZUR-1 follow-up data.